

Electronic Acknowledgement Receipt

EFS ID:	8645712
Application Number:	10719493
International Application Number:	
Confirmation Number:	3218
Title of Invention:	Methods of treating cancer using immunostimulatory oligonucleotides
First Named Inventor/Applicant Name:	Arthur M. Krieg
Correspondence Address:	Helen C. Lockhart, Ph.D. Wolf, Greenfield & Sacks, P.C. 600 Atlantic Avenue - Boston MA 02210 US 6177203500 hlockhart@wolfgreen.com
Filer:	Helen C. Lockhart/Paula Bramwell
Filer Authorized By:	Helen C. Lockhart
Attorney Docket Number:	C1039.70021US01
Receipt Date:	18-OCT-2010
Filing Date:	21-NOV-2003
Time Stamp:	16:25:31
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$ 1290

RAM confirmation Number		2907			
Deposit Account		232825			
Authorized User		LOCKHART,HELEN C			
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	C103970021US01-TRN-HCL.pdf	48786	no	1
			f685807cef4f923ef7a36da3c8108fc35f1e58d9		
Warnings:					
Information:					
2	Fee Worksheet (PTO-875)	C103970021US01-FEE-HCL.pdf	70522	no	1
			5bebc524aaf250a2d647ad0b3cfa804f85d367da		
Warnings:					
Information:					
3	Extension of Time	C103970021US01-EXT-HCL.pdf	55590	no	1
			4438f90c5f0d40335d1e9ab5d65640c88dc6aa4		
Warnings:					
Information:					
4		C103970021US01-AMN-HCL.pdf	556479	yes	12
			1b082ba5ad77b2b6ef0e30436b362aeb00e9cf04		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment/Req. Reconsideration-After Non-Final Reject		1	1	
	Claims		2	5	
	Applicant Arguments/Remarks Made in an Amendment		6	12	
Warnings:					
Information:					
5	NPL Documents	Agrawal_et_al_Clin_Pharm_1995_v28_p7.pdf	692562	no	10
			53003597b0bac6ce15e33c137be6e3685d59220d		
Warnings:					
Information:					
6	NPL Documents	Agrawal_et_al_PNAS_1991_v88_p7595.pdf	315434	no	5
			c29a6d3e7b3590f2f15c503729228ee080f37d5c		

Warnings:					
Information:					
7	NPL Documents	Agrawal_Tibtech_1996_v14_p376.pdf	894569	no	13
			32f8db15867816dff0d91ec5abb5514e5411a3d1		
Warnings:					
Information:					
8	NPL Documents	Brody_et_al_J_Clin_Oncol_2010_v28_p4324.pdf	11356621	no	10
			370b2ae84881c9607874087d9edaee1e0eadd73		
Warnings:					
Information:					
9	NPL Documents	Flieger_FDA_Consumer_report_1995_7_pages.pdf	549939	no	7
			d048cd64d6392c53cb371433a064e7839eb1383f		
Warnings:					
Information:					
10	NPL Documents	Hofmann_et_al_J_Immunother_2008_v31_p520.pdf	9781376	no	8
			8fcdcd24b59d1628cb6e75d8ad2cdc03cd80aaa3b		
Warnings:					
Information:					
11	NPL Documents	Kim_et_al_Blood_2004_v104_Abst_743.pdf	117897	no	2
			32b2ca9c8f1887fdc188f71fba93ae21ee0c329e		
Warnings:					
Information:					
12	NPL Documents	Leonard_et_al_Clin_Cancer_Reviews_2007_v13_p6168.pdf	7163971	no	7
			8fb892418ee1ed8075db4c656eac918beb56bbe6		
Warnings:					
Information:					
13	NPL Documents	Link_et_al_J_Immunother_2006_v29_p558.pdf	12098974	no	11
			7348d4996d1a5e3308a24f763c9e0fda544e0c22		
Warnings:					
Information:					
14	NPL Documents	Manegold_et_al_J_Clin_Oncol_v26_p3979.pdf	8081579	no	8
			52649ede5cd56efbd962032d939a0ecedc998bf0		
Warnings:					
Information:					
15	NPL Documents	Pashenkov_et_al_J_Clin_Oncol_2006_v24_p5716.pdf	9151450	no	9
			d568a2edd66d38b0a3ad6f55358ae82b024da0e0		

Warnings:					
Information:					
16	NPL Documents	Speiser_et_al_J_Clin_Invest_2005_v115_p739.pdf	638165	no	8
			708abdda1459ab24ebac1ace034d76dfd260e72c		
Warnings:					
Information:					
17	NPL Documents	Tokunaga_et_al_Jpn_J_Infect_Dis_1999_v52_p1.pdf	951217	no	12
			d3fd78e3e51db0c515c5f9352fc06d1c5d45850d		
Warnings:					
Information:					
18	NPL Documents	Vlassov_et_al_CRC_Press_1995_ch5_p71.pdf	3246257	no	13
			598a04ec64f32ada5c0064dbfba5231f4b90107b		
Warnings:					
Information:					
19	NPL Documents	C103970074US00_OA_mailed_04-14-2009.pdf	9847334	no	10
			ca16bc1a42a0b49d9b7825588109fe40ee1f86ac		
Warnings:					
Information:					
20	NPL Documents	C103970074US00_OA_mailed_11-19-2009.pdf	13891175	no	14
			551eb8617eb165f7e752f617116c27215ca78e26		
Warnings:					
Information:					
21		C103970021US01-IDS-HCL.pdf	238212	yes	5
			1b1f86526622f813b5f351be257f168ace39e85e		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Transmittal Letter		1	3	
	Information Disclosure Statement (IDS) Filed (SB/08)		4	5	
Warnings:					
Information:					
22	Fee Worksheet (PTO-875)	fee-info.pdf	32304	no	2
			abc160591a32f63d2a0e5f7c1b4c9f354a0886bb		
Warnings:					
Information:					
Total Files Size (in bytes):			89780413		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.